Related by context. All words. (Click for frequent words.) 72 CTAP# Capsules 71 treatment naïve genotype 71 virus HCV 70 chronic HCV infection 69 LymphoStat B belimumab 69 refractory gout 69 forodesine 68 ACTEMRA TM 67 CYT# potent vascular disrupting 67 virus HCV protease inhibitor 67 sorafenib tablets 67 decompensated liver disease 66 evaluating tivozanib 66 HIV coinfected 66 HGS ETR1 mapatumumab 66 HCV NS5B polymerase 66 Ribavirin causes 66 BARACLUDE ® 66 relapsed multiple myeloma 66 nucleoside naive 66 hepatitis C HCV 66 chronic hepatitis C 66 discontinued Viread 66 leukemia AML 66 ribavirin therapy 66 e antigen HBeAg 66 non nucleoside inhibitor 66 erlotinib Tarceva ® 66 systemically administered 66 AEG# 66 Aflibercept 65 treatment naive genotype 65 Amgen Neulasta R 65 LymphoStat B TM 65 antibody MAb 65 dasatinib Sprycel ® 65 nucleotide analog 65 novel VDA molecule 65 dirucotide MBP# 65 diarrhea predominant irritable 65 HBeAg negative 65 huC# DM4 65 receiving immunosuppressive therapy 65 candidate XP# 65 personalized cellular immunotherapy 65 AA Amyloidosis 65 metastatic hormone refractory 65 lintuzumab SGN 65 delivers fluocinolone acetonide FA 65 KRAS mutations occur 65 acetonide FA 65 INSPIRE Trial Phase III 65 oral ghrelin agonist 65 elotuzumab 65 chronic HBV 65 recurrent glioblastoma multiforme 65 oral ridaforolimus 65 radezolid 65 trastuzumab DM1 T DM1 65 essential thrombocythemia ET 65 Naive Patients 65 Myelodysplastic Syndrome MDS 65 Amgen Neulasta ® 65 myelodysplastic myeloproliferative diseases 65 cell lymphoma CTCL 65 orally administered inhibitor 65 advanced hepatocellular carcinoma 65 pan HDAC inhibitor 65 toenail onychomycosis 64 RG# nucleoside analog 64 generation NNRTI 64 refractory chronic lymphocytic 64 adalimumab Humira 64 BENLYSTA TM 64 cSSSIs 64 hyperphenylalaninemia HPA due 64 COU AA 64 PNP inhibitor 64 cirrhosis liver failure 64 SPRYCEL ® 64 HQK 64 systemic fungal infections 64 receptor tyrosine kinase inhibitor 64 oral prodrug 64 Hsp# Inhibitor 64 refractory cutaneous T 64 IMA# 64 alvespimycin 64 relapsed MM 64 non splenectomized 64 dose cohort 64 humanized interleukin 6 64 nitazoxanide 64 candidemia 64 IMiDs ® 64 epithelial tumors 64 diabetic neuropathic pain 64 CCR5 antagonist 64 albinterferon alfa 2b 64 alemtuzumab treated 64 cutaneous T 64 SNT-MC#/idebenone 64 Initiates Phase II 64 mRCC 64 Omacetaxine 64 taxane resistant 64 oropharyngeal candidiasis OPC 64 ALN TTR 64 chronic eosinophilic leukemia 64 kidney urologic 64 lexidronam injection 64 Elotuzumab 64 davunetide intranasal AL 64 PEGylated interferon beta 1a 64 Chronic hepatitis C 64 Myelodysplastic syndromes MDS 63 oral nucleoside analogue 63 HCV SPRINT 63 Hepatitis C HCV 63 either acutely decompensated 63 FOLOTYN ® 63 peginterferon alfa 2a Pegasys 63 PRTX 63 HCV genotype 1 63 Sudhir Agrawal D.Phil 63 dasatinib Sprycel 63 metastatic castration resistant 63 investigational oral hepatitis C 63 demonstrated antitumor activity 63 HBeAg positive 63 inhibitor RG# 63 MKC# MT 63 rALLy clinical trial 63 refractory CLL 63 CCR9 antagonist 63 relapsing remitting MS RRMS 63 imatinib Gleevec ® 63 MAGE A3 ASCI 63 polymerase inhibitor 63 trastuzumab Herceptin R 63 post herpetic neuralgia PHN 63 advanced metastatic renal 63 INCB# [001] 63 trastuzumab Herceptin ® 63 null responder HCV 63 Hepatitis C virus HCV 63 autoantibody positive 63 nucleotide analogue 63 agonistic human 63 NS5b 63 protease inhibitor telaprevir 63 castrate resistant prostate cancer 63 neuroendocrine cancers 63 ALN HPN 63 tumors GIST 63 mGluR5 NAM 63 phase IIb study 63 unique alkylating agent 63 chronic HBV infection 63 Chronic Hepatitis C 63 nucleoside analog 63 Copegus ribavirin 63 FOLFOX6 chemotherapy regimen 63 ZOLINZA 63 AAG geldanamycin analog 63 pegylated interferon alpha 63 RANK Ligand inhibitor 63 HGS ETR2 63 alfa 2a 63 metastatic renal cell 63 cetuximab Erbitux R 63 Pafuramidine 63 methylnaltrexone bromide 63 HCV protease inhibitor 63 chronic hepatitis C. 63 bridging fibrosis 63 BARACLUDE R 63 CIMZIA ™ 63 SCH # 63 ALN PCS 63 lamivudine refractory patients 63 gastrointestinal stromal tumor GIST 63 glioblastoma multiforme GBM 63 nosocomial pneumonia 63 Pegasys ® 63 CCR5 tropic HIV 63 phase IIb trial 63 ORENCIA ® 63 Altastaph 63 cariprazine 63 relapsed leukemia 63 metaglidasen 63 SHPT 63 Solazed TM 63 hepatitis C genotype 63 MGd 63 hepatocellular carcinoma HCC 62 Tezampanel 62 MT#/MEDI-# 62 MEK Inhibitor 62 OHR/AVR# 62 papillary renal cell carcinoma 62 relapsed refractory multiple myeloma 62 brivanib 62 topical gel formulation 62 ocular formulation 62 vapreotide acetate 62 compound INCB# 62 GAMMAGARD 62 pancreatic NET 62 lenalidomide Revlimid R 62 PREZISTA r 62 oral proteasome inhibitor 62 fallopian tube carcinoma 62 HCV infections 62 thetreatment 62 unresectable stage 62 invasive candidiasis 62 mcg BID 62 recurrent glioblastoma 62 pegylated interferon alfa 2a 62 doripenem 62 DermaVir Patch 62 HER2 positive metastatic breast 62 OMNARIS HFA 62 hepatitis B HBV 62 modified glutathione analog 62 APTIVUS r 62 chronic HCV genotype 62 sunitinib Sutent ® 62 ara C 62 Pegasys peginterferon alfa 2a 62 Doxil ® 62 cIAI 62 smoldering multiple myeloma 62 PEGylated Fab fragment 62 HCV genotypes 62 prokinetic agent 62 naïve HCV 62 talactoferrin 62 Traficet EN 62 metastatic renal cell carcinoma 62 Oral Fingolimod 62 CIMZIA TM 62 selective modulator 62 anti botulism antibody 62 immunomodulatory therapy 62 Ozarelix 62 TNF antagonist 62 receiving VELCADE 62 familial amyloidotic polyneuropathy FAP 62 Nexavar sorafenib 62 Diabetic Macular Edema 62 antiretroviral naïve 62 sorafenib Nexavar 62 INCB# [003] 62 methicillin resistant S. aureus 62 docetaxel chemotherapy 62 XL# XL# 62 Phase IIb clinical trials 62 RhuDex ® 62 XL# anticancer compounds 62 Allovectin 7 R 62 albiglutide 62 acyclovir Lauriad R 62 relapsed refractory AML 62 leukemia ALL 62 hypereosinophilic syndrome 62 MVA HPV IL2 62 stage IIIB 62 refractory multiple myeloma 62 LymphoStat B 62 MAXY alpha 62 primary hypercholesterolemia 62 rheumatoid arthritis psoriatic arthritis 62 pegylated interferon alpha 2a 62 Cethromycin 62 hour bronchodilation 62 Personalized Immunotherapy 62 Recombinant interferon alpha 62 histone deacetylase HDAC inhibitor 62 Seliciclib 62 ritonavir boosted 62 prostate cancer HRPC 62 stage IIIb IV 62 liver transplantations 62 HBeAg negative patients 62 Lymphocytic 62 humanized monoclonal antibody 62 Archexin 62 Telbivudine 62 naive HCV 62 Philadelphia Chromosome Positive 62 vinca alkaloid 62 Pharmacokinetics PK 62 Cutaneous T 62 HBeAg positive patients 62 metastatic neuroendocrine tumors 62 alpha interferons 62 8mg/kg 62 diarrhea CDAD 62 alkylating agent 62 RSD# oral 62 anticancer compound 62 leukemia CLL 62 budesonide foam 62 CEQ# 62 adult chronic ITP 62 TRO# 62 abacavir lamivudine 62 Oracea TM 62 chronic hepatitis B. 62 CIMZIA TM certolizumab pegol 62 PHX# 61 Alinia 61 Daclizumab 61 gastrointestinal disorders ATI 61 Plicera 61 RRMS patients 61 JAK2 Inhibitor 61 multicenter Phase II 61 RhuDex R 61 somatostatin analog 61 metastatic colorectal carcinoma 61 K ras mutations 61 oral candidiasis 61 Aptivus ® 61 Fibrillex TM 61 disease CDAD 61 lead Aganocide compound 61 Evoltra ® 61 bevacizumab Avastin ® 61 AVONEX ® 61 CCR5 mAb 61 PROSTVAC VF 61 hyaluronidase enzyme 61 mcg doses 61 PegIFN RBV 61 Vitrasert ® 61 oral rivaroxaban 61 phase IIb clinical 61 mixed dyslipidemia 61 Ophena TM 61 genotype 1b 61 primary immunodeficiency PI 61 hepatocellular cancer 61 steroid refractory ulcerative 61 AA amyloidosis 61 Lubiprostone 61 recurrent genital herpes 61 oral picoplatin 61 valsartan amlodipine 61 Phase 1b trial 61 Sapacitabine 61 PDX pralatrexate 61 Xanafide 61 Blinatumomab 61 Hepatocellular Carcinoma HCC 61 Vascular Disrupting Agent 61 dose intramuscular 61 pancreatic neuroendocrine tumors 61 null responder 61 thiazolides 61 Renal Cell Carcinoma RCC 61 Phase #b/#a clinical 61 CD# CEA 61 simplex virus 61 Panzem R 61 COPEGUS ribavirin 61 SinuNase ™ 61 plus COPEGUS 61 Amrubicin 61 terlipressin 61 orally inhaled migraine 61 elevated ALT 61 opioid induced constipation OIC 61 tenofovir emtricitabine 61 Hepsera adefovir dipivoxil 61 PORxin TM platforms 61 HBV infections 61 recurrent NSCLC 61 SAR# [004] 61 LEUKINE 61 teriflunomide 61 Completes Patient Enrollment 61 ruboxistaurin 61 proteasome inhibitor 61 oral FTY# 61 gastric adenocarcinoma 61 unresectable tumors 61 refractory metastatic 61 invasive fungal infections 61 Viread tenofovir disoproxil fumarate 61 metastatic GIST 61 stage IIIB IV 61 micafungin 61 reduce serum phosphate 61 JNJ Q2 61 antiangiogenesis therapies 61 Interferon alpha 61 PEGINTRON TM 61 Idiopathic pulmonary fibrosis 61 Safinamide 61 Teriflunomide 61 bladder ovarian 61 aflibercept VEGF Trap 61 registrational trial 61 μg dose 61 Akt inhibitor 61 Initiates Clinical Trial 61 anti PlGF 61 lymphoma CTCL 61 AML MDS 61 systemic RNAi therapeutic 61 protein tyrosine phosphatase 1B 61 subcutaneously administered 61 compound ITMN 61 clinical trials SGN 61 interferon alfa 61 PROSTASCINT R 61 leading oral taxane 61 2 methoxyestradiol 61 Idiopathic Pulmonary Fibrosis IPF 61 Chronic hepatitis B 61 non alcoholic steatohepatitis 61 alpha folate receptor 61 Initiates Enrollment 61 coinfected 61 Prodarsan R 61 YONDELIS 61 Bezielle 61 TBC# 61 purpura ITP 61 multicenter Phase III 61 evaluating REVLIMID 61 Systemic lupus erythematosus SLE 61 Veronate R 61 castration resistant prostate cancer 61 mcg albinterferon alfa 2b 61 Annamycin 61 HCV Protease Inhibitor 61 Allovectin 7 61 Hodgkin lymphoma HL 61 PEG INTRON R 61 novel histone deacetylase 61 elevated triglyceride levels 61 Phase 2b Clinical Trial 61 Sebivo 61 sodium thiosulfate STS 61 MT# MEDI 61 Chronic Hepatitis B 61 Clostridium difficile associated 61 Aviptadil 61 Epothilone D 61 pediatric acute lymphoblastic 61 oral JAK#/JAK# inhibitor 61 Begins Dosing 61 AEGR 61 Ceflatonin R 61 TELINTRA 61 infliximab monotherapy 61 hepatitis C polymerase inhibitor 61 ribavirin RBV 61 visilizumab 61 Cloretazine 61 PKC# 61 Enzastaurin 61 Lactic acidosis 61 Phase Ib clinical 61 Aztreonam lysine 61 posaconazole 61 sodium glucose cotransporter 61 C1 INH deficiency 61 lucinactant 61 virus XMRV 61 carcinoid syndrome 61 eosinophilic asthma 61 investigational protease inhibitor 61 therapeutic monoclonal antibody 61 include Healive TM 61 refractory NSCLC 61 protease inhibitor PI 61 Epstein Barr virus EBV 61 metastatic malignant melanoma 61 Nitazoxanide 61 Voreloxin 60 SUTENT 60 chronic HCV 60 myocardial infarction ventricular fibrillation 60 Talabostat 60 Natalizumab 60 ELACYT 60 arthritis PsA 60 MEK inhibitor 60 receiving XGEVA 60 chlamydial infections 60 esophageal candidiasis 60 Chronic HCV infection 60 monoclonal antibody conjugated 60 Velcade bortezomib 60 cirrhosis scarring 60 ZACTIMA 60 virus HBV 60 apricitabine 60 Navelbine ® 60 HGS ETR1 60 cardio renal 60 constipation OIC 60 Systemic Sclerosis 60 VELCADE melphalan 60 MELAS 60 huN# DM1 60 Xcytrin R 60 Glufosfamide 60 mertansine 60 antiangiogenic therapy 60 JAK2 inhibitor 60 TELINTRA R 60 Azilect ® 60 EDEMA3 60 thalidomide Thalomid 60 nevirapine Viramune 60 lesinurad 60 targeted radiotherapeutic 60 posterior uveitis 60 metastatic gastric 60 IRX 2 60 Pseudomonas aeruginosa infections 60 DU #b 60 heavily pretreated 60 HCV infection 60 PSMA ADC 60 non metastatic osteosarcoma 60 evaluating T DM1 60 Escherichia coli Klebsiella pneumoniae 60 velafermin 60 latent tuberculosis infection 60 docetaxel Taxotere ® 60 Brentuximab Vedotin SGN 60 Combination REOLYSIN R 60 depsipeptide 60 gefitinib Iressa 60 chronic hepatitis 60 myelofibrosis polycythemia vera 60 Campath alemtuzumab 60 Hepatitis C Virus HCV 60 Ovitrelle R Serostim 60 Mg Uk 60 essential thrombocythemia 60 telaprevir VX 60 RhuDex ™ 60 riociguat 60 PEGASYS ® 60 Xyfid TM 60 pediatric Crohn disease 60 Myocet 60 Vicinium TM 60 oral deforolimus 60 liposomal formulation 60 Tolvaptan 60 R MSCRAMM 60 generation radiolabeled antibody 60 VEGFR2 inhibitor 60 OncoVEX GM CSF 60 sarcoma melanoma 60 receiving INTRON 60 Vicriviroc 60 Gemzar ® 60 basal cell carcinoma BCC 60 chronic granulomatous disease 60 Cariprazine 60 antiretroviral naive 60 TACI Ig 60 dosing cohorts 60 orally bioavailable 60 biodefense pathogens 60 beta 1a 60 oncolytic virus therapies 60 REGN# 60 weekly subcutaneous injections 60 hepatitis B virus HBV 60 colorectal liver metastases 60 systemic lupus erythematosus SLE 60 Telaprevir VX 60 IMPDH inhibitor 60 Racivir 60 severe malignant osteopetrosis 60 panitumumab Vectibix 60 de novo kidney transplant 60 IMiDs R 60 Crohn disease CD 60 ceftazidime 60 selective kinase inhibitor 60 Romidepsin 60 ketolide antibiotic 60 product candidate Lpathomab 60 molecular imaging radiopharmaceutical 60 PANVAC VF 60 human IgG1 monoclonal 60 RAPTIVA 60 zidovudine AZT 60 JVRS 60 Genentech Rituxan 60 topically applied SEPA 60 Actemra tocilizumab 60 Phase 1a clinical 60 multi kinase inhibitor 60 systemic ALCL 60 pralatrexate injection folate analogue 60 GVAX ® 60 mitogen activated ERK kinase 60 metastatic HRPC 60 neovascular diseases 60 microbiological eradication 60 overactive bladder syndrome 60 hepatorenal syndrome 60 refractory chronic myeloid 60 Cervista HPV HR 60 Telintra 60 IMiDs ® compound 60 Oral NKTR 60 catheter occlusion 60 Carfilzomib 60 Metastatic Melanoma 60 TLR7 agonist 60 plus DOXIL 60 Pegasys plus Copegus 60 chlorambucil 60 Randomized Phase 60 HGS# 60 Civacir 60 Elvitegravir 60 secretory phospholipase A2 60 JAK inhibitor 60 TYZEKA 60 trastuzumab emtansine T DM1 60 Triapine R 60 relapsing multiple sclerosis 60 Haptoglobin 60 pulmonary Pseudomonas aeruginosa 60 Pradefovir 60 peginterferon alfa 2a 60 myeloproliferative disorders 60 Luveris R Ovidrel R 60 sulodexide 60 HER2 overexpression 60 fulminant hepatitis 60 systemic anaplastic large 60 ug dose 60 R#/MEM # 60 Virulizin ® 60 including eniluracil ADH 60 Myelodysplastic syndromes 60 triciribine phosphate monohydrate 60 Phase Ib clinical trials 60 metastatic carcinoid 60 Epstein Barr Virus EBV 60 Phase 2a clinical 60 hepatitis C viral infection 60 commercialize deforolimus 60 lopinavir r arm 60 HIV RDEA# 60 pentadentate logo R 60 Chronic lymphocytic leukemia 60 TransVax TM 60 investigational humanized monoclonal antibody 60 intravenous RSD# 60 mapatumumab 60 R sorafenib tablets 60 overt nephropathy 60 Maribavir 60 HCV RESPOND 2 60 oncogenic HPV 60 CANCIDAS 60 Tumour Vascular Disrupting Agent 60 Combivir Kivexa 60 Investigational Oral 60 Hereditary angioedema HAE 60 CB2 selective receptor agonist 60 Skin Structure Infections ABSSSI 60 psoriatic arthritis PsA 60 cisplatin gemcitabine 60 Aganocide 60 investigational integrase inhibitor 60 developing Zerenex TM 60 PRT# 60 CRMD# 60 Empatic ™ 60 LHRH antagonists 60 Entereg R 60 Degarelix 60 anti amnesic 60 Fx #A 60 pharmacokinetic PK study 60 beta2 agonist 60 genotypic resistance 60 Clevudine 60 PDE4 inhibitor 60 varicella zoster virus VZV 60 pegylated interferons 60 intranasal formulation 60 refractory AML 60 situ CIS 60 SNT MC# 60 delafloxacin 60 diabetic nephropathy 60 sorafenib Nexavar ® 60 non metastatic resectable 60 aggressive systemic mastocytosis 60 Insegia 60 TM Aganocide 60 ThermoDox R 60 smoldering myeloma 60 MTP inhibitor 60 multiple myeloma MM 60 SUVN 59 gastrin analogue TT 59 plus Copegus R 59 Staphylococcus aureus infections 59 investigational hepatitis C 59 vaginal candidiasis 59 severe hepatomegaly 59 infection sinusitis 59 damage cirrhosis liver 59 Genasense ® 59 adecatumumab MT# 59 PEG Interferon lambda 59 P#X# antagonist 59 diabetic gastroparesis 59 metastatic colorectal 59 Phase #/#a trial 59 alefacept 59 CYP#A# CYP#D# 59 acute myelogenous leukemia AML 59 Streptococcus pneumoniae pneumococcus 59 S. aureus bloodstream infections 59 Vandetanib 59 bacterial respiratory infections 59 lupus renal disease 59 included exfoliative dermatitis 59 mg administered orally 59 personalized dendritic cell 59 Hedgehog Pathway Inhibitor 59 metastatic pancreatic 59 Ceftaroline 59 Phenoptin 59 Relapsed Refractory 59 cilengitide 59 mGluR2 positive 59 CMV disease 59 dacetuzumab SGN 59 phase IIa 59 hepatitis C virus HCV 59 antisense inhibitors 59 markets Testim ® 59 humanised monoclonal antibody 59 elvucitabine 59 Peginterferon 59 Cell Lymphoma CTCL 59 initiated Phase Ib 59 Chronic Lymphocytic Leukemia CLL 59 viral subtypes 59 S. aureus isolates 59 TNFerade ™ 59 Provectus Pharmaceuticals specializes 59 etanercept Enbrel 59 prostate cancer CRPC 59 protease inhibitors PIs 59 induced mucositis 59 idiopathic pulmonary fibrosis IPF 59 evaluating picoplatin 59 ISTODAX ® 59 neratinib 59 #I TM# 59 haematologic malignancies 59 skeletal metastases 59 generation Hsp# inhibitor 59 receptor inhibiting monoclonal 59 THR beta agonist 59 neuropathic pain spasticity 59 mild vasodilator 59 coinfected patients 59 lumiliximab 59 secondary hyperparathyroidism 59 Microplasmin 59 dose escalation clinical 59 TNF antagonist therapy 59 Initiate Phase 59 Cimzia TM 59 investigational monoclonal antibody 59 Opportunistic infections 59 Radezolid 59 nucleoside analogues 59 gastrointestinal stromal tumors GIST 59 GW# [003] 59 recurrent glioma 59 SCIg 59 ILUVIEN ® 59 XL# XL# XL# XL# 59 Multiple Myeloma MM 59 Phase Ib II 59 MCSP respectively 59 Systemic lupus erythematosus 59 P aeruginosa 59 world safest multivalent 59 ALN VSP Phase 59 peripheral blood mononuclear 59 NRTI resistance 59 transthyretin mediated amyloidosis ATTR 59 Clostridium difficile infection 59 DIRECT Trial 59 Cannabinor 59 Shigatoxin producing E. coli 59 non squamous NSCLC 59 relapsing remitting multiple sclerosis 59 Cholangiocarcinoma 59 apoptosis inducer 59 indolent follicular non 59 zanolimumab 59 GRN# 59 omega interferon 59 efalizumab 59 chronic ITP patients 59 headache nasopharyngitis 59 Quinamed 59 Laquinimod 59 acute humoral rejection 59 celgosivir 59 vidofludimus 59 secondary hyperparathyroidism SHPT 59 PROCHYMAL 59 lupus nephritis 59 ribavirin Copegus 59 methicillin resistant MRSA 59 carcinoid tumors 59 HCV infected 59 immunosuppressed patients 59 Phase Ib IIa 59 macroalbuminuria 59 HCV polymerase inhibitors 59 PEG PAL 59 DEB# 59 phase III ACCLAIM 59 glucocorticoid induced osteoporosis 59 Complicated Skin 59 thromboembolic complications 59 Acute Myelogenous Leukemia AML 59 baminercept 59 MPS IVA 59 NATRECOR ® 59 dyslipidaemia 59 radiation sensitizer 59 BCR ABL inhibitor 59 lymphoid malignancies 59 HuMax CD4 59 Engerix B 59 Chronic HCV 59 Reverset 59 Budesonide foam crofelemer 59 GSK '# 59 sapacitabine CYC# 59 substantially excreted 59 FTY# fingolimod 59 ponatinib 59 herpes zoster shingles 59 Prodarsan ® 59 bortezomib Velcade R 59 Myelofibrosis 59 4SC AG ISIN DE# 59 basiliximab 59 Tarceva TM 59 TLR9 agonist 59 Gleevec resistant 59 SPL# Gel vaginal microbicide 59 superficial bladder cancer 59 Romiplostim 59 LTBI 59 Kit CD# positive 59 standard chemotherapy regimen 59 liver histology 59 plus methotrexate 59 transcriptase inhibitor NNRTI 59 REMINYL ® 59 HBeAg negative chronic hepatitis 59 vWD 59 ALN TTR# 59 Phase IIb trials 59 measurable tumor regressions 59 TTR gene 59 serum phosphate 59 Fabry Disease 59 NASDAQ SNTA 59 Clolar ® 59 PI3K/Akt pathway inhibitor 59 pan histone deacetylase 59 TYGACIL 59 Acute myeloid leukemia 59 trial evaluating PRX# 59 assessing T DM1 59 sunitinib Sutent 59 Golimumab 59 placebo controlled Phase III 59 pemphigus vulgaris 59 Phase 2a clinical trials 59 LHRH receptor positive 59 NOX E# 59 IPL# 59 Aurexis 59 virological response 59 imatinib Gleevec 59 INTEGRILIN R 59 AzaSite Plus 59 XOMA 3AB 59 malignant pleural mesothelioma 59 Tasimelteon 59 sunitinib malate 59 CYP#A# substrate 59 PEG IFN 59 VISICOL R 59 carcinoid 59 Iluvien ® 59 targeting CD# 59 leukemia APL 59 MYDICAR ® 59 Virologic 59 human rhinovirus HRV 59 investigational compounds 59 immuno inflammatory diseases 59 isoform selective 59 RGB # 59 Bucindolol 59 ongoing Phase 1b 59 dependent kinase inhibitor 59 mg RDEA# 59 orally administered synthetic retinoid 59 methicillin susceptible 59 polycythemia vera PV 59 Chronic Idiopathic Constipation 59 sJIA 59 MyVax R 59 Trofex TM 59 polysaccharide polymer 59 sustained virological response 59 Familial Adenomatous Polyposis FAP 59 apricitabine ATC 59 paclitaxel cisplatin 59 Factor VIIa 59 interleukin IL -# 59 stage IIIb 59 metastatic malignant 59 #mg BID [001] 59 Raptiva r 59 Pruvel TM 59 Antiviral Activity 59 forodesine hydrochloride 59 opioid induced constipation 59 atypical Hemolytic Uremic Syndrome 59 relapsed CLL 59 coinfection 59 AGILECT R 59 RNAi therapeutic targeting 59 erythematosus 59 cetuximab Erbitux ® 59 Thiovir 59 complement inhibitor eculizumab 59 Apaziquone 59 AZT zidovudine Retrovir 59 MEK inhibitor RDEA# 59 androgen receptor antagonist 59 chronic plaque psoriasis 59 #mg QD [001] 59 Phase 2a trial 59 RNAi Therapeutic 59 COPEGUS therapy 59 generation purine nucleoside 59 pseudobulbar affect PBA 59 hormone LHRH antagonist 59 Phase #b/#a trial 59 Phase 1b clinical 59 fosbretabulin 59 metastatic renal 59 chronic idiopathic thrombocytopenic purpura 59 postmenopausal osteoporotic women 59 relapsed SCLC 59 CTA# Injection 59 hyperuricemia 59 Perifosine 59 TG# [003] 59 FS Antihemophilic Factor Recombinant 59 refractory CTCL 59 cMET 59 KSP inhibitor 59 initiate Phase 1b 59 IAP inhibitor 59 systemic lupus erythematosus psoriasis 59 Telik logo TELINTRA 59 OMP #R# 59 thymalfasin 59 GATTEX ®